Omvax, Inc.

San Francisco, CA

UEI
MKQKRT751Q19
CAGE
7CGX6
Primary NAICS
325414 Biological Product (except Diagnostic) Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1700 Montgomery St #108, San Francisco, CA 94111, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
A next-generation meningococcal serogroup b vaccine with improved effectiveness for all age groups R44AI124759 National Institute of Allergy and Infectious Diseases (NIH) $6,000,000
A universal vaccine for the prevention of meningococcal meningitis in africa R41AI124759 National Institute of Allergy and Infectious Diseases (NIH) $264,826
Novel vaccine approaches for n. Meningitidis disease R01AI046464 National Institute of Allergy and Infectious Diseases (NIH) $11,741,685

Quick answers

Is Omvax, Inc. registered in SAM.gov?

Yes. Omvax, Inc.'s SAM.gov registration is active through July 6, 2027.

What is Omvax, Inc.'s most recent federal award?

Omvax, Inc.'s most recent federal grant award is A next-generation meningococcal serogroup b vaccine with improved effectiveness for all age groups (R44AI124759), from National Institute of Allergy and Infectious Diseases (NIH), on July 8, 2016.

On GovTribe

See Omvax, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login